DANVERS, Mass.--(BUSINESS WIRE)-- Three cardiac surgeons at Cleveland Clinic, Hackensack Meridian Health and Cedars-Sinai Medical Center are the first in the United States to implant Abiomed’s (NASDAQ ...

DANVERS, Mass.--(BUSINESS WIRE)-- Abiomed (Nasdaq: ABMD) announces the first patient in the world has been successfully implanted with Impella Bridge-to-Recovery (BTR) as part of the heart pump’s U.S.

Abiomed, Inc. ABMD recently announced the receipt of two approvals from the FDA, which are related to clinical research of Impella heart pumps in acute myocardial infarction (AMI) cardiogenic shock ...

DANVERS, Mass., Abiomed, Inc. a leading provider of breakthrough heart recovery and support technologies, announced today that the Impella 5.5™ heart pump received CE marking1 approval in Europe and ...

Cardiac surgeons at Hackensack (N.J.) University Medical Center, part of the Hackensack Meridian health system, performed the first-in-human Impella RP Flex heart pump implant on Nov. 8. The patient, ...

Hackensack Meridian Health, Hackensack University Medical Center cardiac surgeon Yuriy Dudiy, M.D. became the second in the world to successfully implant the Impella Bridge-to-Recovery (BTR)™ heart ...

With the Transcatheter Cardiovascular Therapeutics (TCT) symposium firmly at the forefront, news relating to FDA nods for cardiovascular companies seems to be pouring in. Abiomed announced two ...

Johnson & Johnson’s Abiomed division has received its second Class I recall designation from the FDA in as many months. The agency’s label is reserved for issues with a heightened risk of injury or ...

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Johnson & Johnson said Monday that a pivotal trial for the ...